Farxiga metformin
Pro Research Analysisby 
Searched over 200M research papers for "farxiga metformin"
Farxiga and Metformin: A Comprehensive Overview
Introduction to Farxiga (Dapagliflozin) and Metformin
Farxiga, known generically as dapagliflozin, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used to manage type 2 diabetes mellitus (T2DM). It works by inhibiting the renal reabsorption of glucose, thereby increasing glucose excretion through urine and lowering blood glucose levels independently of insulin secretion . Metformin, on the other hand, is a first-line medication for T2DM that improves insulin sensitivity and reduces hepatic glucose production.
Efficacy of Farxiga Alone and in Combination with Metformin
Glycemic Control
Dapagliflozin has been shown to effectively lower A1C levels. When used alone, it reduces A1C by an average of 0.7 percentage points. When combined with metformin, the reduction is slightly lower, averaging 0.5 percentage points . This combination therapy is particularly beneficial for patients who are inadequately controlled on metformin alone.
Weight Reduction and Hypoglycemia Risk
One of the advantages of dapagliflozin is its association with weight reduction, which is a significant benefit for many T2DM patients. Additionally, it has a low propensity to cause hypoglycemia, making it a safer option for many patients .
Cost-Effectiveness of Farxiga and Metformin Combination
A study assessing the long-term cost-effectiveness of dapagliflozin added to metformin compared with sulfonylurea (SU) added to metformin in Nordic countries found that the combination of metformin and dapagliflozin is cost-effective. The cost per quality-adjusted life year (QALY) gained with dapagliflozin and metformin was favorable across Denmark, Finland, Norway, and Sweden, with QALY gains ranging from 0.236 to 0.278 . This indicates that the combination not only improves health outcomes but does so in a cost-effective manner.
Safety and Adverse Effects
General Tolerability
Dapagliflozin is generally well tolerated, with an adverse event profile similar to placebo in clinical trials. However, it is associated with an increased risk of genital and urinary tract infections .
Bladder Cancer and Diabetic Ketoacidosis
There is an observed association between dapagliflozin and an increased risk of bladder cancer, although most cases were diagnosed within the first year of exposure. Additionally, there is a noted risk of diabetic ketoacidosis, a serious condition that requires careful monitoring 24.
Conclusion
Farxiga (dapagliflozin) combined with metformin offers a promising treatment option for patients with type 2 diabetes mellitus. It effectively lowers A1C levels, promotes weight loss, and has a low risk of hypoglycemia. Moreover, it is a cost-effective alternative to other combination therapies. However, patients and healthcare providers should be aware of the potential risks, including genital infections, urinary tract infections, and a possible increased risk of bladder cancer and diabetic ketoacidosis. Ongoing research and post-marketing surveillance will continue to clarify these risks and optimize the use of dapagliflozin in clinical practice.
Sources and full results
Most relevant research papers on this topic